Kosei Hasegawa, MD, PhD
1 clinical trials · Sponsor
◉ Watch Kosei Hasegawa, MD, PhD
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer (NCT05158062) | Kosei Hasegawa, MD, PhD | 2022-04-20 |
Track Kosei Hasegawa, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.